Recombinant platelet collagen receptor glycoprotein vi and its pharmaceutical use
CA 2372515 C · Owner: Aventis Pharma Deutschland Gmbh · Inventors: Clemetson, Kenneth J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to Glycoprotein VI (GPVI) its isolation, purification, and methods for recombinant production. Especially the invention relates to , the use of GPVI preferably recombinant GPVI, in the treatment of disorders and pathological events correlated directly or indirectly to blood coagulation disorders such as thrombotic and cardiovascular diseases. The extracellular recombinant protein can also be used for establishing screening assays to find potential inhibitors of the membrane bound GPVI in order to inhibit binding of thrombocytes and platelets, respectively to collagen. Changes in GPIV can be , used to monitor platelet age and exposure to thrombotic and …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 25, 2000 and granted December 1, 2015. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 25, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 25, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.